Search Bar & Filters
Found 34 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with fluoropyrimidine and trastuzumab deruxtecan T-DXd compared to trastuzumab, chemotherapy, and pembrolizumab in participants with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 combined positive score CPS of 1 or higher. This Phase 3, randomized, open-label study also includes a separate group receiving rilvegostomig with trastuzumab and chemotherapy to understand the contribution of each treatment component. The study is being conducted globally across many sites in about 25 countries. Participants are assigned to one of three treatment groups Arm A receives rilvegostomig, fluoropyrimidine capecitabine or 5-fluorouracil, and trastuzumab deruxtecan Arm B receives pembrolizumab, trastuzumab, and chemotherapy 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin Arm C receives rilvegostomig, trastuzumab, and chemotherapy. Treatments are administered mainly through intravenous infusions every three weeks, with capecitabine taken orally twice daily. The study aims to assess the role of each treatment combination over time. During the study, participants will undergo regular assessments including tumor measurements, safety checks for adverse events, and blood tests to monitor drug levels and immune responses. Researchers will track progression-free survival and overall survival for up to six years, along with response rates and treatment side effects. The study includes ongoing monitoring for eating difficulties and side-effect impact. Participants will be followed closely throughout treatment and for years afterward to evaluate long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. This Phase 1 open-label study aims to assess how safe and tolerable ASP3082 is when given alone or with other treatments like cetuximab. The study includes people who have received prior standard therapies or are ineligible for them, focusing on determining appropriate doses and treatment combinations. The study is divided into two parts. In Part 1, small groups of participants receive increasing doses of ASP3082 alone or with cetuximab through intravenous infusion in 21-day cycles to find suitable dosing levels. In Part 2, participants receive ASP3082 alone or combined with other therapies such as FOLFIRINOX, Nab-paclitaxel plus gemcitabine, docetaxel, pembrolizumab, platinum-based chemotherapy with pemetrexed, or NALIRIFOX, with dosing based on Part 1 findings. Treatment continues until intolerable side effects, disease progression, starting other cancer treatments, or participant decision to stop. Participants will undergo regular assessments including monitoring for side effects, laboratory tests, electrocardiograms, physical exams, and performance status evaluations for up to 48 months. Researchers will measure dose-limiting toxicities, adverse events, and tumor response using standard criteria. Tumor samples will be collected before and during treatment to assess KRAS G12D changes. The study monitors safety and treatment effects closely throughout participation, which may last several years.
Actively Recruiting
Researchers are evaluating BH-30643, a new oral drug designed to target specific mutations in the EGFR and HER2 genes in patients with advanced or metastatic non-small cell lung cancer NSCLC. This Phase 12 open-label study aims to assess the safety, how the body processes the drug, and its early anti-tumor effects. Phase 1 focuses on finding the right dose, both alone and combined with chemotherapy, while Phase 2 further examines effectiveness and safety in groups defined by mutation type and treatment history. Participants receive BH-30643 either alone or with CarboplatinPemetrexed chemotherapy. Phase 1 includes dose escalation and expansion to determine the recommended dose for Phase 2. In Phase 2, BH-30643 is given at this recommended dose to evaluate its antitumor activity. The study monitors drug levels in the blood and observes responses to treatment over time. Throughout the study, participants undergo regular evaluations including imaging scans to measure tumor size, blood tests to monitor drug levels and organ function, and assessments of side effects and quality of life. Researchers track safety continuously from enrollment until study completion, approximately four years. The main outcomes include identifying dose-limiting toxicities, determining the best dose, and measuring tumor response rates.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ifinatamab deruxtecan I-DXd combined with the immune checkpoint inhibitor atezolizumab, with or without carboplatin, in adults with extensive stage-small cell lung cancer ES-SCLC. This study includes two parts Part A focuses on safety and dose finding, while Part B aims to optimize the dose of I-DXd in combination with atezolizumab and carboplatin. The study targets participants in the first-line treatment setting of ES-SCLC. Participants may be assigned to different groups depending on prior treatment. Some will receive maintenance therapy with I-DXd and atezolizumab after standard induction therapy, while others who are newly diagnosed and treatment-naive will receive induction therapy combining I-DXd, atezolizumab, and carboplatin followed by maintenance therapy. The doses of I-DXd vary between 8 mgkg and 12 mgkg given intravenously every three weeks. The study includes a safety monitoring period when dosing the first participants. During the study, participants will have regular visits for treatment administration and safety assessments. Researchers will monitor adverse events, treatment tolerability, and detailed measures such as progression-free survival, response rates, and overall survival over approximately 37 months. Additional evaluations include imaging scans, biopsies, laboratory tests, and pharmacokinetic blood sampling. Participants are expected to comply with study procedures, including biopsies for some groups and contraception requirements for those of childbearing potential.
Actively Recruiting
Researchers are evaluating the efficacy and safety of ifinatamab deruxtecan I-DXd in adults with unresectable advanced or metastatic esophageal squamous cell carcinoma ESCC who have experienced disease progression after treatment with platinum-based chemotherapy and immune checkpoint inhibitors. This phase 3 clinical trial compares I-DXd to the investigators choice of chemotherapy in this patient group to assess overall survival benefits. Participants are randomly assigned to receive either intravenous infusions of I-DXd at 12 mgkg every 21 days or investigator-selected chemotherapy drugs such as docetaxel, paclitaxel, or irinotecan hydrochloride. Treatment cycles repeat every three weeks, continuing until disease progression or other study endpoints. The study will measure overall survival, progression-free survival, objective response rate, duration of response, disease control rate, quality of life changes, safety events, and pharmacokinetic parameters for up to approximately 54 months. Throughout the study, participants will undergo regular assessments including imaging scans to measure tumor lesions, quality of life questionnaires, and safety monitoring for adverse events. Blood samples will be collected to analyze drug levels and immune responses. The studys main outcome is overall survival from randomization to death from any cause. Participants health and response to treatment will be followed closely during and after treatment for up to 54 months, with continued monitoring of safety and effectiveness measures.
Actively Recruiting
Researchers are evaluating how well vortioxetine, given at doses of 10 mg or 20 mg daily, works compared to a placebo for treating depression symptoms in Japanese teenagers aged 12 to 17 years diagnosed with Major Depressive Disorder MDD. The study aims to assess both the effectiveness and side effects of the medication in this population. Participants will take either vortioxetine or a placebo orally once a day for 14 weeks. The treatment starts at 10 mg per day and may be increased to 20 mg per day. After the treatment period, there is a 4-week phase to monitor for any side effects. The study includes a total of 13 clinic visits during the participation period. Throughout the study, participants will be regularly assessed using various tools including the Children Depression Rating Scale Revised version CDRS-R, Patient Health Questionnaire-9 for Adolescents PHQ-A, Digit Symbol Substitution Test DSST, and Clinical Global Impression scales. Blood samples will be taken to measure plasma levels of vortioxetine. The entire participation lasts about 20 weeks, including up to 2 weeks for screening, 14 weeks of treatment, and 4 weeks of post-treatment follow-up to check safety.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and how the body processes zipalertinib in adults with locally advanced or metastatic Non-Small Cell Lung Cancer NSCLC that has specific mutations in the EGFR gene called exon 20 insertions and other uncommon mutations. This Phase 2b study includes participants with different prior treatment histories and brain metastases to understand how zipalertinib works in these groups. The study also explores possible interactions between zipalertinib and other drugs and aims to identify the best dose for treatment. Participants are divided into four main groups based on their mutation type and treatment history. They receive zipalertinib orally twice daily continuously until disease progression or other reasons for stopping. Additional substudies enroll participants to evaluate drug interactions using special probe medications and to optimize dosing by randomly assigning participants to different dose groups. The dosing cycles last 21 days, and treatments continue as long as criteria are met. Throughout the study, participants undergo regular assessments including tumor measurements, brain imaging for those with brain metastases, heart monitoring with ECG and scans, laboratory tests, and evaluation of side effects. Researchers measure outcomes such as tumor response rates, disease control, progression-free survival, and overall survival for up to two years. Safety is closely monitored by tracking adverse events and changes in vital signs and organ function. Participants remain under observation during treatment and follow-up periods until study completion.
1-10 of 34
1